Nuvectis Pharma raises $15.5 million to advance oncology drug candidates NXP800 and NXP900.
Read more
Globus Medical acquires Nevro for $250M to expand in chronic pain management with neuromodulation platforms.
Read more
Aprea Therapeutics strengthens IP portfolio for DNA Damage Response cancer therapeutics, advancing ATR and WEE1 inhibitor programs.
Read more
AdvanCell partners with Lilly to develop targeted alpha therapies for Cancer using Pb-212 technology.
Read more
Immunovant advances IMVT-1402 trials in Graves' Disease and Rheumatoid Arthritis with six INDs cleared.
Read more
Erasmus Medical Center approves Phase 2 trial of Ampligen and Imfinzi for late-stage Pancreatic Neoplasms.
Read more
NEJM publishes eNRGy trial results for BIZENGRI, FDA-approved for NRG1+ Pancreatic Adenocarcinoma and NSCLC.
Read more
Onc.AI's AI model receives FDA Breakthrough Device Designation for improving survival predictions in metastatic non-small cell lung cancer.
Read more
Cure Rare Disease receives $5.69M CIRM grant to advance gene therapy for Spinocerebellar Ataxia Type 3.
Read more
OliX and Lilly partner to develop OLX75016 for Metabolic-Associated Steatohepatitis and cardiometabolic conditions.
Read more
Kura and Kyowa Kirin report positive results for ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia.
Read more
Cumberland's ifetroban improves cardiac function in Duchenne Muscular Dystrophy Phase II trial.
Read more
Zenocutuzumab shows durable efficacy in NRG1 fusion-positive pancreatic adenocarcinoma and NSCLC, published in NEJM.
Read more
CAR T-cell therapy market projected to grow to $15.2 billion by 2035, driven by CD19 and BCMA target antigens.
Read more
IO Biotech publishes preclinical data on IO112, a cancer vaccine targeting Arginase 1, with IND submission expected in 2025.
Read more
SelectQuote secures $350M investment from Bain Capital, Morgan Stanley, and Newlight to expand healthcare services.
Read more
Eli Lilly partners with AdvanCell and OliX to advance radiopharmaceuticals and Metabolic-Associated Steatohepatitis (MASH) treatments.
Read more
Algiax's AP-325 shows promising results in Phase 2a trial for Neuropathic Pain, offering rapid and lasting relief without opioid risks.
Read more
Cusatuzumab leads Phase II trials for Acute Myeloid Leukemia, advancing CD70-targeting therapies in oncology.
Read more
AI discovers new protein compounds effective against bacterial and fungal infections in mice, aiding antimicrobial resistance fight.
Read more
FDA grants priority review to Insmed's Brensocatib for Bronchiectasis, with action date set for August 12, 2025.
Read more
Boehringer's nerandomilast meets primary endpoint in Phase III trial for Progressive Pulmonary Fibrosis.
Read more
MIT project funded to develop algorithms enhancing cerebrospinal fluid flow to combat neurodegeneration in aging.
Read more
FDA approves EMBLAVEO for complicated intra-abdominal infections with limited treatment options.
Read more
Cotiviti to acquire Edifecs, enhancing healthcare data interoperability and value-based care solutions.
Read more
